{"id":997784,"date":"2026-08-25T08:12:12","date_gmt":"2026-08-25T12:12:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-corporate-update-webinar-on-september-2-2026\/"},"modified":"2026-08-25T08:12:12","modified_gmt":"2026-08-25T12:12:12","slug":"annovis-to-host-corporate-update-webinar-on-september-2-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-corporate-update-webinar-on-september-2-2026\/","title":{"rendered":"Annovis to Host Corporate Update Webinar on September 2, 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p>MALVERN, Pa., Aug.  25, 2026  (GLOBE NEWSWIRE) &#8212; Annovis Bio, Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD), today announced it will host a corporate update webinar followed by a live Q&amp;A session.<\/p>\n<p>The webinar will provide an overview of the Company\u2019s recent progress, ongoing clinical programs, and upcoming milestones.<\/p>\n<p>\n        <strong>Webinar details<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>Date: Wednesday, September 2, 2026<\/li>\n<li>Time: 4:00 p.m. EDT<\/li>\n<li>Presenter: Maria Maccecchini, Ph.D., Founder, President, and CEO<\/li>\n<li>\n          <a href=\"https:\/\/zoom.us\/webinar\/register\/WN_QRF6xO03S9GwsDvpfsxsog\" rel=\"nofollow\" target=\"_blank\">Registration link<\/a>\n        <\/li>\n<\/ul>\n<p>&#8220;Annovis is advancing across all its programs, and it is important to share the full scope of that progress with our community,&#8221; commented Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. &#8220;Several key milestones have been reached: our pivotal Phase 3 AD trial is fully enrolled, and preparations are already underway for the top-line data readout and regulatory submissions, both expected in 2027. We also plan to continue our AD program into an open-label study to generate long-term safety data for buntanetap, with first patients joining in October 2026. On the PD side, the open-label study is well underway, and discussions with Key Opinion Leaders and the FDA are ongoing to initiate the Parkinson&#8217;s disease dementia program. As we move forward, we are committed to keeping our patient community, stockholders, and everyone following our progress informed at every step.&#8221;<\/p>\n<p>\n        <strong>About Annovis<\/strong><br \/>\n        <br \/>Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer&#8217;s disease (AD) and Parkinson&#8217;s disease (PD). The Company&#8217;s lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PtukpQakNiKNIPBjxq_PsdY3I06O0MfQhdtad0WKYNIA4w7ldcQ90zC6RK1uTAwBzI5v-ilPk-SiQGHTAm-KtdnH2y9JXzwISKZKw0RjQPwcnX56so-YbQlRmA5Nhf7onUlE8wV3L-Dsc25cQENOKifDJh646ANmpcTd_AmQEZ-jIFrtH1GnYoZhCtjW0fVbn4PVcEE5BG9IA4c7behM-yup369EoBVO6AHij6OiD1D3C1SJQvS-5sddp37jN-fsKDvMzE0nAHyKQIA-5E5paw==\" rel=\"nofollow\" target=\"_blank\">www.annovisbio.com<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QXHMnoUuFkJ1vNymfEcqZOwf0lUpTOgRUEyzfen0vaR-apvfzQjb8yPF_e4yHpN2Zpca6PppYXmAvSbiycBgwifWZSOiSaB-nSRaoQSshfsbPwiiEzU39p4YsEuoD21ZWnk09BxWRxjb2BUSU5QYDCj07ul-Z7BZ2dYZYBDQ4aD53mFUwpipAkFS2N7i1fr6VB4A1RL-opBQLodLPsEXirti7b7D3heNXtaPjFy8JmUUvyDIKU0Pqwy727usGQJ5NAr7rJ7qWclgHcaMqfi6lEajxGgzfQSI3Wf7PG_EyviWzmQxu3vPbNSmuXJu9qq2\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fW1rQm5RjFFooatpTvIruphpuVe6vzTsemghYksGIG0ddWguyp6MN6Tz69AVnTjmIqvNdGz-A0fxCePh4EehNLGKDiEGrSyPCjP7f-ijR5fOiSoxQEaOhfeBwqlitDygMZlkXn5jDtbu0Q4ASf64IDwB4NszVY31p4Nhx4VQkpaxXiaxEetO9KOGNhYq07P8LSFhj4UzeOo6exf5nBuxTe1APsZw2JUktif531nvkTJmj7i3d-WkaAUILByFweoa\" rel=\"nofollow\" target=\"_blank\">YouTube<\/a>, and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=piDEwloDwJvbj4AfdaIEQ9tJ2_RIFd6xUA6MI_WdsO3d6IhJVc1SJnBMBorQwDKjo5CauBFBsuKpbGlvFEdt9-irq_0uot3IjQLfLhL61xKSndtTt1zgqtxy5pC_egucHsnxTcix5TL24cAXgbDfOfSa5NifJEy_ulFbefCvMzMcw40sJZmeMXc99NEejxggWC-2in02REY-BiCziphDVg==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p>\n        <strong>Investor Alerts<\/strong><br \/>\n        <br \/>Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UW2jSgq7v38OBz8zJNg6ut5cyajtX15Ozr5qc7uoxRi52Vufg_0I880pdg3Zu1QuIy70xmeIz4aVm9vf-xeONH5dyOUYgPgDZ2X1flYbf9wODjbo_T1wkyGUk6SIyfhXbwLFg1CNnwp6xIWpT5xDw63RgTT6dNNU_QyaowGL_T3cWkHSymC5TcZQiGPZbCd6vVmBbH8Qyho3_r0eJDFooq1UgmENlCEU6Id4DK0BzISQLKDgYKoMqdsylsNXPUMI5KZPLRld1gBLG4rbuFIycX_6L9B5l5g9FrJQWkSfMfUqc2-shXDbIwV3YmziLOIjtG7YT80nUuj4_wC57bAtjpaRdKhK-ApOtZ2clY27tr4=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.annovisbio.com\/email-alerts<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company\u2019s SEC filings under \u201cRisk Factors\u201d in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.<\/p>\n<p>\n        <strong>Contact Information:<\/strong><br \/>\n        <br \/>Annovis Bio Inc.<br \/>101 Lindenwood Drive<br \/>Suite 225<br \/>Malvern, PA 19355<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PtukpQakNiKNIPBjxq_PsV-teMrGsTpMQAig0v_7Jl4K_-LSZNoNdrtkam3Sbu5HdJjXgSAsI8bvgf8_b99_5Y7bMShS3K1OcEaJRrde-pU_2STJgNqiO1kM5bJKsHttS7jIJHf3qOPdpUwmE6BYgmYz9SnCY9ye0kr75Ox7YGoPCnVvg2BKwHrpi1JYUmoUAyVnkh5nGW90Mac-6gGQyx6zCwXHBKtjmtoDHegRotoFDJNog4Mh6-GfFUS8cpaieYQe3YxI2xg98RJLELz_ew==\" rel=\"nofollow\" target=\"_blank\">www.annovisbio.com<\/a><\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Alexander Morin, Ph.D.<br \/>Director, Strategic Communications<br \/>Annovis Bio<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=F-R_S4wj-x4BK0E2G5fentbLT3pUkKnpQ_BR80RmrUkYZPIIU_9uT1GuHUxAO-RmfVgv84lnSiMov9QPF6FPYu0bzBpKBG1KWtYiZ8IHXYY=\" rel=\"nofollow\" target=\"_blank\">ir@annovisbio.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNTQ1MSM3ODAxNjQxIzIxOTQ4NTA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OWU3MmJiODctMDM4NS00M2JkLTlkYjUtYTcxMWIxOGY4ZTc0LTEyMDY0MDMtMjAyNi0wOC0yNS1lbg==\/tiny\/Annovis-Bio-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) &#8212; Annovis Bio, Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD), today announced it will host a corporate update webinar followed by a live Q&amp;A session. The webinar will provide an overview of the Company\u2019s recent progress, ongoing clinical programs, and upcoming milestones. Webinar details Date: Wednesday, September 2, 2026 Time: 4:00 p.m. EDT Presenter: Maria Maccecchini, Ph.D., Founder, President, and CEO Registration link &#8220;Annovis is advancing across all its programs, and it is important to share the full scope of that progress with our community,&#8221; commented Maria Maccecchini, Ph.D., &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-corporate-update-webinar-on-september-2-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Annovis to Host Corporate Update Webinar on September 2, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-997784","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Annovis to Host Corporate Update Webinar on September 2, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-corporate-update-webinar-on-september-2-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Annovis to Host Corporate Update Webinar on September 2, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) &#8212; Annovis Bio, Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD), today announced it will host a corporate update webinar followed by a live Q&amp;A session. The webinar will provide an overview of the Company\u2019s recent progress, ongoing clinical programs, and upcoming milestones. Webinar details Date: Wednesday, September 2, 2026 Time: 4:00 p.m. EDT Presenter: Maria Maccecchini, Ph.D., Founder, President, and CEO Registration link &#8220;Annovis is advancing across all its programs, and it is important to share the full scope of that progress with our community,&#8221; commented Maria Maccecchini, Ph.D., &hellip; Continue reading &quot;Annovis to Host Corporate Update Webinar on September 2, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-corporate-update-webinar-on-september-2-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-25T12:12:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNTQ1MSM3ODAxNjQxIzIxOTQ4NTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-host-corporate-update-webinar-on-september-2-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-host-corporate-update-webinar-on-september-2-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Annovis to Host Corporate Update Webinar on September 2, 2026\",\"datePublished\":\"2026-08-25T12:12:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-host-corporate-update-webinar-on-september-2-2026\\\/\"},\"wordCount\":469,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-host-corporate-update-webinar-on-september-2-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxNTQ1MSM3ODAxNjQxIzIxOTQ4NTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-host-corporate-update-webinar-on-september-2-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-host-corporate-update-webinar-on-september-2-2026\\\/\",\"name\":\"Annovis to Host Corporate Update Webinar on September 2, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-host-corporate-update-webinar-on-september-2-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-host-corporate-update-webinar-on-september-2-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxNTQ1MSM3ODAxNjQxIzIxOTQ4NTA=\",\"datePublished\":\"2026-08-25T12:12:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-host-corporate-update-webinar-on-september-2-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-host-corporate-update-webinar-on-september-2-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-host-corporate-update-webinar-on-september-2-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxNTQ1MSM3ODAxNjQxIzIxOTQ4NTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxNTQ1MSM3ODAxNjQxIzIxOTQ4NTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-host-corporate-update-webinar-on-september-2-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Annovis to Host Corporate Update Webinar on September 2, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Annovis to Host Corporate Update Webinar on September 2, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-corporate-update-webinar-on-september-2-2026\/","og_locale":"en_US","og_type":"article","og_title":"Annovis to Host Corporate Update Webinar on September 2, 2026 - Market Newsdesk","og_description":"MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) &#8212; Annovis Bio, Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD), today announced it will host a corporate update webinar followed by a live Q&amp;A session. The webinar will provide an overview of the Company\u2019s recent progress, ongoing clinical programs, and upcoming milestones. Webinar details Date: Wednesday, September 2, 2026 Time: 4:00 p.m. EDT Presenter: Maria Maccecchini, Ph.D., Founder, President, and CEO Registration link &#8220;Annovis is advancing across all its programs, and it is important to share the full scope of that progress with our community,&#8221; commented Maria Maccecchini, Ph.D., &hellip; Continue reading \"Annovis to Host Corporate Update Webinar on September 2, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-corporate-update-webinar-on-september-2-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-25T12:12:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNTQ1MSM3ODAxNjQxIzIxOTQ4NTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-corporate-update-webinar-on-september-2-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-corporate-update-webinar-on-september-2-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Annovis to Host Corporate Update Webinar on September 2, 2026","datePublished":"2026-08-25T12:12:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-corporate-update-webinar-on-september-2-2026\/"},"wordCount":469,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-corporate-update-webinar-on-september-2-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNTQ1MSM3ODAxNjQxIzIxOTQ4NTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-corporate-update-webinar-on-september-2-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-corporate-update-webinar-on-september-2-2026\/","name":"Annovis to Host Corporate Update Webinar on September 2, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-corporate-update-webinar-on-september-2-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-corporate-update-webinar-on-september-2-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNTQ1MSM3ODAxNjQxIzIxOTQ4NTA=","datePublished":"2026-08-25T12:12:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-corporate-update-webinar-on-september-2-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-corporate-update-webinar-on-september-2-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-corporate-update-webinar-on-september-2-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNTQ1MSM3ODAxNjQxIzIxOTQ4NTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNTQ1MSM3ODAxNjQxIzIxOTQ4NTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-corporate-update-webinar-on-september-2-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Annovis to Host Corporate Update Webinar on September 2, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/997784","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=997784"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/997784\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=997784"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=997784"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=997784"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}